Condition: Advanced Biliary Tract Cancer
Intervention: Other: oxaliplatin, 5-fluorouracil and bevacizumab plus Toripalimab
Sponsor: Peking University
Not yet recruiting
Feeds
13523 items (13523 unread) in 74 feeds
Acinar Cell Carcinoma
(178 unread)
Acinic Cell Carcinoma
(71 unread)
Adenoid Cystic Carcinoma
(271 unread)
Adrenal Gland Cancer
(1132 unread)
Ampulla Of Vater
(127 unread)
Anal Cancer
(1026 unread)
Angiosarcoma
(358 unread)
Appendix Cancer
(230 unread)
Bile Duct Cancer
(1886 unread)
Brain and CNS
(1849 unread)
Carcinoid
(487 unread)
Endocrine/Neuroendocrine
(1365 unread)
Gall Bladder Cancer
(632 unread)
Hemangioendothelioma
(313 unread)
Hepatoblastoma
(197 unread)
Pancreas
(259 unread)
Phyllodes
(156 unread)
PMP and Mucinous Tumors
(147 unread)
Rhabdomyosarcoma
(615 unread)
Sarcoma
(2224 unread)
Trials - Gall Bladder Cancer (16 unread)
-
Hepatic Arterial Infusion Chemotherapy With FOLFOX and Bevacizumab Plus Toripalimab Intravenously for Advanced Biliary Tract Cancer
Posted: January 6th, 2020, 3:00pm GMT
-
Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor
Posted: January 1st, 2020, 3:00pm GMT
Conditions: HER-2 Protein Overexpression; HER-2 Gene Amplification
Interventions: Drug: Trastuzumab biosimilar; Drug: Gemcitabine Hydrochloride; Drug: Irinotecan Hydrochloride
Sponsors: Jin-Hee Ahn; Asan Medical Center
Not yet recruiting -
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Posted: December 25th, 2019, 3:00pm GMT
Condition: Advanced Biliary Tract Cancer
Intervention: Drug: Toripalimab plus Lenvatinib
Sponsors: Peking Union Medical College Hospital; Shanghai Junshi Biosciences Co., LTD
Not yet recruiting -
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Posted: December 18th, 2019, 3:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: CPI 613; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: University of Michigan Rogel Cancer Center
Not yet recruiting -
Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA
Posted: December 3rd, 2019, 3:00pm GMT
Condition: Gallbladder Carcinoma
Interventions: Drug: gemcitabine and oxaliplatin.; Drug: Afatinib
Sponsors: Shanghai Jiao Tong University School of Medicine; Shanghai Zhongshan Hospital; Ruijin Hospital
Recruiting -
Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Posted: August 26th, 2019, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma; Advanced Gallbladder Carcinoma; Advanced Malignant Solid Neoplasm; Metastatic Cholangiocarcinoma; Metastatic Gallbladder Carcinoma; Metastatic Malignant Solid Neoplasm; Refractory Cholangiocarcinoma; Refractory Gallbladder Carcinoma; Refractory Malignant Solid Neoplasm; Stage III Gallbladder Cancer AJCC v8; Stage III Hilar Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Hilar Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Hilar Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIC Hilar Cholangiocarcinoma AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Hilar Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVA Hilar Cholangiocarcinoma AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Stage IVB Hilar Cholangiocarcinoma AJCC v8
Interventions: Drug: Avelumab; Radiation: Hypofractionated Radiation Therapy; Drug: Nedisertib
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC)
Posted: August 26th, 2019, 2:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Interventions: Drug: Bintrafusp alfa; Drug: Placebo; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting -
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
Posted: July 1st, 2019, 2:00pm GMT
Condition: Biliary Tract Carcinoma
Interventions: Drug: Pembrolizumab; Drug: Gemcitabine; Drug: Cisplatin; Drug: Placebo
Sponsor: Merck Sharp & Dohme Corp.
Recruiting -
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
Posted: May 6th, 2019, 2:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Biological: 'SMT-NK' Inj (allogeneic Natural Killer cell); Drug: Pembrolizumab Injection [Keytruda]
Sponsor: SMT bio Co., Ltd.
Recruiting -
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
Posted: February 7th, 2019, 3:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention: Drug: M7824
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Recruiting -
Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
Posted: October 24th, 2018, 2:00pm GMT
Conditions: Pancreatic Cancer; Resectable Pancreatic Cancer
Interventions: Drug: Pimonidazole; Procedure: Surgical Resection
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Varian Medical Systems
Not yet recruiting -
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
Posted: May 4th, 2017, 2:00pm GMT
Conditions: Cancer-associated Thrombosis; Esophageal Cancer; Stomach Cancer; Hepatocellular Carcinoma; Pancreatic Cancer; Duodenal Cancer; Esophagogastric Junction Cancer; Malignant Gastrointestinal Stromal Tumor; Ampulla of Vater Cancer; Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)
Interventions: Drug: Rivaroxaban; Drug: Dalteparin; Drug: apixaban
Sponsor: Asan Medical Center
Recruiting -
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Posted: April 13th, 2017, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Liver Cancer; Gallbladder Cancer
Interventions: Biological: Pembrolizumab (MK-3475); Drug: Oxaliplatin; Drug: Capecitabine
Sponsor: National Cancer Institute (NCI)
Recruiting -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Chile Biliary Longitudinal Study
Posted: February 26th, 2016, 3:00pm GMT
Conditions: Gallbladder Cancer; Nutritional and Metabolic Diseases
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting -
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
Posted: March 11th, 2011, 3:00pm GMT
Conditions: Non-GI Cancers; Cancer of Gastrointestinal Tract; Gastrointestinal Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting